Neurogenic overactive bladder in spinal cord injury and multiple sclerosis: role of onabotulinumtoxinA

Neurogenic overactive bladder is a common issue for people with multiple sclerosis (MS) and spinal cord injury (SCI). This condition can lead to significant problems such as social isolation and recurrent infections. Traditional treatments haven't always been effective or well-tolerated. Therefore, researchers have explored the use of botulinum toxin A (specifically onabotulinumtoxinA) as a treatment option. OnabotulinumtoxinA has shown promise in reducing urinary incontinence, decreasing detrusor pressures, and improving bladder capacity, leading to a better quality of life for individuals with neurogenic overactive bladder.

• 1
  OnabotulinumtoxinA significantly decreases post-void residuals at 1 month from 251.8 mL to 153.0 mL, and decreases detrusor pressures from 88.7 cm H2O to 20.5 cm H2O.
• 2
  Phase III studies reported dramatic results in both groups when compared with placebo for the primary outcome measure of decreased urinary incontinence at 6 weeks (P,0.001).
• 3
  Quality of life is consistently and markedly improved by use of onabotulinumtoxinA for neurogenic overactive bladder.